[Management of Raynaud's phenomenon].
Lazareth
I
I
Unité de Médecine Vasculaire et d'Hypertension Artérielle, Service de Médecine Interne, Hôpital Saint-Joseph, 185, rue Raymond Losserand, 75014 Paris.
D000328:Adult; D017677:Age Distribution; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016285:Iloprost / Q000627:therapeutic use; D019808:Losartan / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009336:Necrosis; D011379:Prognosis; D011928:Raynaud Disease / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D012307:Risk Factors; D017678:Sex Distribution; D012907:Smoking / Q000009:adverse effects; D014665:Vasodilator Agents / Q000627:therapeutic use; D014700:Verapamil / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D014665:Vasodilator Agents; D014700:Verapamil; D016285:Iloprost; D019808:Losartan